Literature DB >> 28478038

Successful metformin treatment of insulin resistance is associated with down-regulation of the kynurenine pathway.

Otto Muzik1, Paul Burghardt2, Zhengping Yi3, Ajay Kumar4, Berhane Seyoum5.   

Abstract

CONTEXT: An extensive body of literature indicates a relationship between insulin resistance and the up-regulation of the kynurenine pathway, i.e. the preferential conversion of tryptophan to kynurenine, with subsequent overproduction of diabetogenic downstream metabolites, such as kynurenic acid. CASE DESCRIPTION: We have measured the concentration of kynurenine pathway metabolites (kynurenines) in the brain and pancreas of two young (27 and 28 yrs) insulin resistant, normoglycemic subjects (M-values 2 and 4 mg/kg/min, respectively) using quantitative C-11-alpha-methyl-tryptophan PET/CT imaging. Both subjects underwent a preventive 12-week metformin treatment regimen (500 mg daily) prior to the PET/CT study. Whereas treatment was successful in one of the subject (M-value increased from 2 to 12 mg/kg/min), response was poor in the other subjects (M-value changed from 4 to 5 mg/kg/min). Brain and pancreas concentrations of kynurenines observed in the responder were similar to that in a healthy control subject, whereas kynurenines determined in the non-responder were about 25% higher and similar to those found in a severely insulin resistant patient. Consistent with this outcome, M-values were negatively correlated with both kynurenic acid levels (R2 = 0.68, p = 0.09) as well as with the kynurenine to tryptophan ratio (R2 = 0.63, p = 0.11).
CONCLUSION: The data indicates that kynurenine pathway metabolites are increased in subjects with insulin resistance prior to overt manifestation of hyperglycemia. Moreover, successful metformin treatment leads to a normalization of tryptophan metabolism, most likely as a result of decreased contribution from the kynurenine metabolic pathway. Published by Elsevier Inc.

Entities:  

Keywords:  AMT PET imaging; Insulin resistance; Kynurenine pathway; Tryptophan metabolism

Mesh:

Substances:

Year:  2017        PMID: 28478038      PMCID: PMC5554450          DOI: 10.1016/j.bbrc.2017.04.155

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  16 in total

Review 1.  Alpha[C-11]methyl-L-tryptophan PET maps brain serotonin synthesis and kynurenine pathway metabolism.

Authors:  D C Chugani; O Muzik
Journal:  J Cereb Blood Flow Metab       Date:  2000-01       Impact factor: 6.200

2.  Evaluation of indoleamine 2,3-dioxygenase expression and kynurenine pathway metabolites levels in serum samples of diabetic retinopathy patients.

Authors:  Praveen Kumar Munipally; Satish G Agraharm; Vijay Kumar Valavala; Sridhar Gundae; Naga Raju Turlapati
Journal:  Arch Physiol Biochem       Date:  2011-10-29       Impact factor: 4.076

3.  Nanomolar concentrations of kynurenic acid reduce extracellular dopamine levels in the striatum.

Authors:  Arash Rassoulpour; Hui-Qiu Wu; Sergi Ferre; Robert Schwarcz
Journal:  J Neurochem       Date:  2005-05       Impact factor: 5.372

Review 4.  Adipose tissue macrophages, low grade inflammation and insulin resistance in human obesity.

Authors:  Leonie K Heilbronn; Lesley V Campbell
Journal:  Curr Pharm Des       Date:  2008       Impact factor: 3.116

5.  Imaging epileptogenic tubers in children with tuberous sclerosis complex using alpha-[11C]methyl-L-tryptophan positron emission tomography.

Authors:  D C Chugani; H T Chugani; O Muzik; J R Shah; A K Shah; A Canady; T J Mangner; P K Chakraborty
Journal:  Ann Neurol       Date:  1998-12       Impact factor: 10.422

Review 6.  L-kynurenine: its synthesis and possible regulatory function in brain.

Authors:  E M Gál; A D Sherman
Journal:  Neurochem Res       Date:  1980-03       Impact factor: 3.996

Review 7.  Insulin resistance and dysregulation of tryptophan-kynurenine and kynurenine-nicotinamide adenine dinucleotide metabolic pathways.

Authors:  Gregory Oxenkrug
Journal:  Mol Neurobiol       Date:  2013-06-28       Impact factor: 5.590

8.  Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.

Authors: 
Journal:  Lancet       Date:  1998-09-12       Impact factor: 79.321

9.  Blood-brain barrier transport of kynurenines: implications for brain synthesis and metabolism.

Authors:  S Fukui; R Schwarcz; S I Rapoport; Y Takada; Q R Smith
Journal:  J Neurochem       Date:  1991-06       Impact factor: 5.372

Review 10.  Kynurenic Acid in the digestive system-new facts, new challenges.

Authors:  Michal P Turski; Monika Turska; Piotr Paluszkiewicz; Jolanta Parada-Turska; Gregory F Oxenkrug
Journal:  Int J Tryptophan Res       Date:  2013-09-04
View more
  12 in total

1.  Association of Tryptophan Metabolites with Incident Type 2 Diabetes in the PREDIMED Trial: A Case-Cohort Study.

Authors:  Edward Yu; Christopher Papandreou; Miguel Ruiz-Canela; Marta Guasch-Ferre; Clary B Clish; Courtney Dennis; Liming Liang; Dolores Corella; Montserrat Fitó; Cristina Razquin; José Lapetra; Ramón Estruch; Emilio Ros; Montserrat Cofán; Fernando Arós; Estefania Toledo; Lluis Serra-Majem; José V Sorlí; Frank B Hu; Miguel A Martinez-Gonzalez; Jordi Salas-Salvado
Journal:  Clin Chem       Date:  2018-06-08       Impact factor: 8.327

2.  Peripheral Tryptophan - Kynurenine Metabolism Associated with Metabolic Syndrome is Different in Parkinson's and Alzheimer's Diseases.

Authors:  Gregory Oxenkrug; Marieke van der Hart; Julien Roeser; Paul Summergrad
Journal:  Endocrinol Diabetes Metab J       Date:  2017-11-19

3.  Fluorine-18-Labeled PET Radiotracers for Imaging Tryptophan Uptake and Metabolism: a Systematic Review.

Authors:  Flóra John; Otto Muzik; Sandeep Mittal; Csaba Juhász
Journal:  Mol Imaging Biol       Date:  2020-08       Impact factor: 3.488

Review 4.  Galantamine-Memantine Combination and Kynurenine Pathway Enzyme Inhibitors in the Treatment of Neuropsychiatric Disorders.

Authors:  Michael Y Bai; David B Lovejoy; Gilles J Guillemin; Rouba Kozak; Trevor W Stone; Maju Mathew Koola
Journal:  Complex Psychiatry       Date:  2021-02-08

Review 5.  The Footprint of Kynurenine Pathway in Cardiovascular Diseases.

Authors:  Moein Ala; Seyed Parsa Eftekhar
Journal:  Int J Tryptophan Res       Date:  2022-06-28

6.  Pharmacokinetic-Pharmacometabolomic Approach in Early-Phase Clinical Trials: A Way Forward for Targeted Therapy in Type 2 Diabetes.

Authors:  Khim Boon Tee; Luqman Ibrahim; Najihah Mohd Hashim; Mohd Zuwairi Saiman; Zaril Harza Zakaria; Hasniza Zaman Huri
Journal:  Pharmaceutics       Date:  2022-06-15       Impact factor: 6.525

7.  Association of serum kynurenine/tryptophan ratio with poor glycemic control in patients with type2 diabetes.

Authors:  Sara Abedi; Mahmood Vessal; Fatemeh Asadian; Mohammad Ali Takhshid
Journal:  J Diabetes Metab Disord       Date:  2021-09-12

8.  Metabolomic Analysis of the Improvements in Insulin Secretion and Resistance After Sleeve Gastrectomy: Implications of the Novel Biomarkers.

Authors:  Yeongkeun Kwon; Mi Jang; Youngsun Lee; Jane Ha; Sungsoo Park
Journal:  Obes Surg       Date:  2020-08-19       Impact factor: 4.129

9.  Peripheral kynurenine-3-monooxygenase deficiency as a potential risk factor for metabolic syndrome in schizophrenia patients.

Authors:  Gregory Oxenkrug; Marieke van der Hart; Julien Roeser; Paul Summergrad
Journal:  Integr Clin Med       Date:  2017-05-10

10.  Metformin as an archetype immuno-metabolic adjuvant for cancer immunotherapy.

Authors:  Sara Verdura; Elisabet Cuyàs; Begoña Martin-Castillo; Javier A Menendez
Journal:  Oncoimmunology       Date:  2019-06-25       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.